Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

ProteinN (1)


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 10 records in total 167
    records per page




    CERC-002, a human anti-LIGHT mAb reduces respiratory failure MESHD and death MESHD in hospitalized COVID-19 MESHD ARDS MESHD patients

    Authors: David S. Perlin; Garry A. Neil; Colleen Anderson; Inbal Zafir-Lavie; Lori Roadcap; Shane Raines; Carl Ware; Jeffrey Wilkins

    doi:10.1101/2021.04.03.21254748 Date: 2021-04-07 Source: medRxiv

    Background Severe COVID-19 MESHD infection is associated with dysregulated MESHD immune response which, in a substantial minority of patients, results in cytokine release syndrome ( CRS MESHD) and acute respiratory distress syndrome MESHD ( ARDS MESHD). Inhibition of cytokines or cytokine-associated signal transduction is a promising strategy to ameliorate ARDS MESHD associated with CRS. We and others have previously shown that serum free LIGHT ( TNFSF14 HGNC) levels are markedly elevated in patients with COVID-19 MESHD pneumonia MESHD/ARDS10,11, suggesting that LIGHT neutralization may offer therapeutic benefit to COVID-19 MESHD ARDS MESHD patients. Methods We conducted a randomized, double-blind, placebo-controlled, multi-center, proof-of-concept clinical trial of CERC-002 in adults with mild to moderate ARDS MESHD associated with COVID-19 MESHD (n=83). Enrolled patients received a single dose of CERC-002 or placebo, in addition to standard of care that included high dose corticosteroids. The primary efficacy endpoint was alive and free of respiratory failure MESHD status through Day 28. Secondary outcomes included alive status at Day 28, free of invasive ventilation through Day 28, and serum free LIGHT levels. Results In patients hospitalized with COVID-19 MESHD associated pneumonia MESHD and mild to moderate ( ARDS MESHD), CERC-002 increased the rate of alive and free of respiratory failure MESHD status through Day 28 as compared to placebo (83.9% vs 64.5%; p=0.044). Efficacy was highest in the prespecified subgroup of patients 60 years old and older (76.5% vs 47.1%; p=0.042), the population most vulnerable to severe complications and death MESHD with COVID-19 MESHD infection. Through both the initial 28-day and 60-day follow-up periods, reductions of approximately 50% in mortality were observed for CERC-002 compared to placebo (7.7% vs 14.3% at Day 28 and 10.8% vs 22.5% at Day 60). Importantly, this improvement was incremental to standard of care including high dose steroids and remdesivir 88.0% and 57.8%, respectively). In addition, serum LIGHT levels but not IL-6 HGNC levels were markedly reduced in patients treated with CERC-002. Conclusions The data presented herein demonstrate that CERC-002 markedly reduces the risk of respiratory failure MESHD and death incremental MESHD to standard of care including high dose corticosteroids and reduces LIGHT levels in patients with COVID-19 MESHD ARDS MESHD. (ClinicalTrials.gov number NCT04412057).

    Acute Brain Ischemia MESHD, Infarction and Hemorrhage MESHD in Subjects Dying with or Without Autopsy-Proven Acute Pneumonia MESHD

    Authors: Thomas G Beach; Lucia I Sue; Anthony J Intorcia; Michael J Glass; Jessica E Walker; Richard Arce; Courtney M Nelson; Geidy E Serrano

    doi:10.1101/2021.03.22.21254139 Date: 2021-03-26 Source: medRxiv

    Stroke is one of the most serious complications of Covid-19 MESHD disease but it is still unclear whether stroke MESHD is more common with Covid-19 MESHD pneumonia MESHD as compared to non- Covid-19 MESHD pneumonia MESHD. We investigated the concurrence rate of autopsy-confirmed acute brain ischemia MESHD, acute brain infarction MESHD and acute brain hemorrhage MESHD with autopsy-proven acute non-Covid pneumonia MESHD in consecutive autopsies in the Arizona Study of Aging and Neurodegenerative Disorders MESHD (AZSAND), a longitudinal clinicopathological study of normal aging and neurodegenerative diseases MESHD. Of 691 subjects with a mean age of 83.4 years, acute pneumonia MESHD was histopathologically diagnosed in 343 (49.6%); the concurrence rates for histopathologically-confirmed acute ischemia MESHD, acute infarction MESHD or subacute infarction MESHD was 14% and did not differ between pneumonia MESHD and non-pneumonia MESHD groups while the rates of acute brain hemorrhage MESHD were 1.4% and 2.0% of those with or without acute pneumonia MESHD, respectively. In comparison, in reviews of Covid-19 MESHD publications, reported clinically-determined rates of acute brain infarction MESHD range from 0.5% to 20% while rates of acute brain hemorrhage MESHD range from 0.13% to 2%. In reviews of Covid-19 MESHD autopsy studies, concurrence rates for both acute brain infarction MESHD and acute brain hemorrhage MESHD average about 10%. Covid-19 MESHD pneumonia MESHD and non- Covid-19 MESHD pneumonia MESHD may have similar risks tor concurrent acute brain infarction MESHD and acute brain hemorrhage MESHD when pneumonia MESHD is severe enough to cause death MESHD. Additionally, acute brain ischemia MESHD, infarction MESHD or hemorrhage MESHD may not be more common in subjects dying of acute pneumonia MESHD than in subjects dying without acute pneumonia MESHD.

    Improved Prediction of COVID-19 MESHD Transmission and Mortality Using Google Search Trends for Symptoms in the United States

    Authors: Meshrif Alruily; Mohamed Ezz; Ayman Mohamed Mostafa; Nacim Yanes; Mostafa Abbas; Yasser El-Manzalawy

    doi:10.1101/2021.03.14.21253554 Date: 2021-03-24 Source: medRxiv

    Accurate forecasting of emerging infectious diseases MESHD can guide public health officials in making appropriate decisions related to the allocation of public health resources. Due to the exponential spread of the COVID-19 MESHD infection worldwide, several computational models for forecasting the transmission and mortality rates of COVID-19 MESHD have been proposed in the literature. To accelerate scientific and public health insights into the spread and impact of COVID-19 MESHD, Google released the Google COVID-19 MESHD search trends symptoms open-access dataset. Our objective is to develop 7 and 14 -day-ahead forecasting models of COVID-19 MESHD transmission and mortality in the US using the Google search trends for COVID-19 MESHD related symptoms. Specifically, we propose a stacked long short-term memory (SLSTM) architecture for predicting COVID-19 MESHD confirmed and death MESHD cases using historical time series data combined with auxiliary time series data from the Google COVID-19 MESHD search trends symptoms dataset. Considering the SLSTM networks trained using historical data only as the base models, our base models for 7 and 14 -day-ahead forecasting of COVID cases had the mean absolute percentage error (MAPE) values of 6.6% and 8.8%, respectively. On the other side, our proposed models had improved MAPE values of 3.2% and 5.6%, respectively. For 7 and 14 -day-ahead forecasting of COVID-19 MESHD deaths, the MAPE values of the base models were 4.8% and 11.4%, while the improved MAPE values of our proposed models were 4.7% and 7.8%, respectively. We found that the Google search trends for " pneumonia MESHD," " shortness of breath MESHD," and "fever MESHD" are the most informative search trends for predicting COVID-19 MESHD transmission. We also found that the search trends for " hypoxia MESHD" and " fever MESHD" were the most informative trends for forecasting COVID-19 MESHD mortality.

    Tocilizumab Effect in COVID-19 MESHD Hospitalized Patients: A Systematic Review and Meta-Analysis of Randomized Control Trials

    Authors: Waleed Tharwat Aletreby; Basheer Abdulrahman; Ahmed Fouad Mady; Alfateh Mohammed Noor; Mohammed H Lhmdi; Fahad Faqihi; Abdulrahman M Alharthy; Mohammed A Al-Odat; Dimitrios Karakitsos; Ziad Memish

    doi:10.1101/2021.03.15.21253581 Date: 2021-03-17 Source: medRxiv

    Since the emergence of the first cases of COVID-19 MESHD viral pneumonia MESHD late 2019 several studies evaluated the benefits of different treatment modalities. Early in the pandemic, the interleukin 6 HGNC (IL-6) receptor antibody Tocilizumab was considered in view of the cytokine release syndrome associated with COVID-19 MESHD infection. Several early observational studies showed beneficial effect of treatment with Tocilizumab on mortality, however, results from well-designed randomized clinical trials (RCT) were contradicting. ObjectivesTo perform a systematic literature review and meta-analysis of RCTs utilizing Tocilizumab in the treatment of COVID-19 MESHD pneumonia MESHD, with in-hospital mortality as a primary objective, while secondary objectives included composite outcome of mortality, intubation, or ICU admission, another secondary outcome was super added infection. MethodThis was a random effects model (DerSimonian and Laird) model of relative risk (RR), along with corresponding 95% confidence intervals, p values, and forest plots of both primary and secondary outcomes. A fixed effect sensitivity test was performed for the primary outcome, in addition to subgroup and meta-regression analyses with predefined criteria. ResultsThe primary outcome of mortality showed statistically insignificant reduction of mortality with Tocilizumab (RR = 0.9, 95% CI: 0.8 - 1.01; p = 0.09) although with an unmistakable apparent clinical benefit. There was a significant reduction in the RR of the secondary composite outcome (RR = 0.83, 95% CI: 0.76 - 0.9; p < 0.001), and no difference between groups in super-added infection (RR = 0.77, 95% CI: 0.51 - 1.19; p = 0.24). Treatment protocol allowing a second dose was the only significant predictor of improved mortality in the meta-regression analysis. Certainty of evidence was reduced to moderate for the primary outcome and the secondary outcome of clinical deterioration, while it was reduced to low for the secondary outcome of super-added infection. ConclusionModerate certainty of evidence suggest no statistically significant improvement of 28-30 day all-cause mortality of hospitalized COVID-19 MESHD patients treated with TCZ, although there may be clinically important value. Moderate certainty of evidence suggest lowered relative risk of a composite outcome of death MESHD or clinical deterioration, while, low grade evidence indicate no increase in the risk of super-added infection associated with TCZ treatment. A protocol allowing two doses of TCZ shows evidence of improved mortality as compared to a strictly single dose protocol.

    Comparison of the clinical characteristics and mortality in ARDS MESHD due to COVID-19 MESHD versus ARDS MESHD due to Influenza A-H1N1pdm09

    Authors: CARMEN M HERNANDEZ CARDENAS; GUSTAVO LUGO GOYTIA; DIANA HERNANDEZ; Rogelio Perez-Padilla

    doi:10.1101/2021.02.07.21251306 Date: 2021-02-25 Source: medRxiv

    ImportanceInfection with the SARS-Cov-2 and Influenza A-H1N1 viruses is responsible for the first pandemics of the 21st century. Both of these viruses can cause severe pneumonia MESHD and acute respiratory distress syndrome MESHD ( ARDS MESHD). The clinical differences and mortality associated with these two pandemic pneumonias MESHD in patients with ARDS MESHD are not well established ObjectiveTo compare case-fatality between ARDS MESHD- Covid-19 MESHD and ARDS MESHD-Influenza A (H1N1), adjusting for known prognostic risk factors. Design, Setting and ParticipantsOne hundred forty-seven patients with COVID-19 MESHD were compared with 94 with Influenza A-H1N1, all of these were admitted to the intensive care unit of the Referral Center for Respiratory Diseases MESHD and COVID-19 MESHD in Mexico City and fulfilled the criteria of ARDS MESHD. ResultsPatients arrived at the hospital after 9 days of symptoms. Influenza patients had more obesity MESHD, more use of Norepinephrine, and higher levels of lactic dehydrogenase and glucose, and fewer platelets and lower PaO2/FIO2. Crude mortality was higher in COVID than in influenza (39% vs. 22%; p = 0.005). In a Cox proportional hazard model, patients with a diagnosis of COVID-19 MESHD had a hazard ratio (HR) = 3.7; 95% Confidence Interval [CI] = 1.9-7.4, adjusted for age, gender, sequential organ failure assessment (SOFA) score, ventilatory ratio, and prone ventilation. In the fully adjusted model, the ventilatory ratio and the absence of prone-position ventilation were also predictors of mortality. CONCLUSION COVID-19 MESHD patients treated in an intensive care unit (ICU) had a 3.7 times higher risk of death MESHD than similar patients with Influenza A-H1N1, after adjusting for SOFA score and other relevant risk factors for mortality. QuestionIs the mortality of ARDS MESHD associated with Covid-19 MESHD greater than that of ARDS MESHD associated to influenza H1N1? FindingsIn a Cox proportional hazard model, patients with a diagnosis of COVID-19 MESHD had a hazard ratio (HR) = 3.7; 95% Confidence Interval [CI] = 1.9-7.4, adjusted for age, gender, sequential organ failure assessment (SOFA) score. Meaning COVID-19 MESHD patients treated in an intensive care unit (ICU) had a 3.7 times higher risk of death MESHD than similar patients with Influenza A-H1N1

    Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19 MESHD. A randomized controlled trial

    Authors: Jose Lenin Beltran-Gonzalez; Mario Gonzalez-Gamez; Emmanuel-Antonio Mendoza-Enciso; Ramiro Josue Esparza-Maldonado; Daniel Hernanez-Palacios; Samuel Duenas-Campos; Itzel Ovalle-Robles; Mariana Jocelyn Macias-Guzman; Andrea Lucia Garcia Diaz; Cesar Mauricio Gutierrez Pena; Lucila Martinez-Medina; Victor Manuel Monroy Colin; Jose Manuel Arreola Arreola Guerra

    doi:10.1101/2021.02.18.21252037 Date: 2021-02-23 Source: medRxiv

    Background In the search for active drugs against COVID19 MESHD, the indications of many have been redirected. Ivermectin and Hydroxychloroquine are drugs that inhibit viral replication in vitro and that have been used in several medical centers. Objectives: This clinical trial analyzes the efficacy of Ivermectin and Hydroxychloroquine in patients with moderate COVID19 MESHD and in need of hospitalization. Methods. This a controlled, clinical, randomized, double blind trial that included patients with COVID-19 MESHD-induced pneumonia MESHD and hospitalization criteria, but no severe respiratory failure MESHD. Patients were randomized to one of three groups: Group1 hydroxychloroquine, 400 mg every 12 hours on the first day and subsequently, 200 mg every 12 hours for 4 days, Group 2 ivermectin, 12 mg or 18 mg, according to patient weight and, Group 3 placebo. At inclusion, blood samples for arterial blood gases and biochemical markers associated with a poor prognosis were obtained. The primary outcome was established as the duration of hospitalization until discharge due to patient improvement, the total duration of hospitalization, and the safety outcomes were either respiratory deterioration MESHD or death MESHD. Results. During the month of August, the admission of patients requiring hospitalization mostly encompassed cases with severe respiratory failure MESHD, so we ended the recruitment process and analyzed the data that was available at the time. One hundred and six (106) patients with an average age of 53 yrs. (plus-or-minus sign 16.9) were included, with a greater proportion of males (n=66, 62.2 %). Seventy-two percent (72%) (n= 76) had an associated comorbidity. Ninety percent (90 %) of patients were discharged due to improvement (n=96). The average duration of hospitalization was 6 days (IQR, 3 to 10). No difference in hospitalization duration was found between the treatment groups (Group1: 7 vs Group 2: 6 vs Group 3: 5, p =0.43) nor in respiratory deterioration or death MESHD (Group 1: 18 % vs Group 2: 22.2 % vs Group 3: 24.3 %, p =0.83). Conclusions. In non-critical hospitalized patients with COVID-19 MESHD pneumonia MESHD, neither ivermectin nor hydroxychloroquine decreases the number of in-hospital days, respiratory deterioration MESHD, or deaths MESHD.

    Convalescent plasma for adults with acute COVID-19 MESHD respiratory illness MESHD (CONCOR-1): Study protocol for an international, multicenter, randomized, open-label trial

    Authors: Philippe Bégin; Jeannie Callum; Nancy Heddle; Richard Cook; Michelle P Zeller; Alan Tinmouth; Dean Fergusson; Melissa M Cushing; Marshall J Glesby; Michaël Chassé; Dana V Devine; Nancy Robitaille; Renée Bazin; Nadine Shehata; Andrés Finzi; Allison McGeer; Damon Scales; Lisa Schwartz; Alexis F Turgeon; Ryan Zarychanski; Nick Daneman; Richard Carl; Luiz Amorim; Caroline Gabe; Martin Ellis; Erin Jamula; Julie Carruthers; Joanne Duncan; Kayla Lucier; Chantal Armali; Amie Kron; Dimpy Modi; Marie-Christine Auclair; Meda Avram; Donald M Arnold

    doi:10.21203/rs.3.rs-268937/v1 Date: 2021-02-23 Source: ResearchSquare

    Background: Convalescent plasma has been used for numerous viral diseases including influenza, severe acute respiratory syndrome MESHD, Middle East respiratory syndrome MESHD and Ebola virus MESHD; however, evidence to support its use is weak. SARS-CoV-2 is a novel coronavirus responsible for the 2019 global pandemic of COVID-19 MESHD community acquired pneumonia MESHD. We have undertaken a randomized controlled trial to assess the efficacy and safety of COVID-19 MESHD convalescent plasma (CCP) in patients with SARS-CoV-2 infection MESHD.Methods: CONCOR-1 is an open-label, multicenter, randomized trial. Inclusion criteria include: patients >16 years; admitted to hospital with COVID-19 MESHD infection; receiving supplemental oxygen for respiratory complications of COVID-19 MESHD; and, availability of blood group compatible CCP. Exclusion criteria are: onset of respiratory symptoms more than 12 days prior to randomization; intubated or planned for intubation; and previous severe reactions to plasma. Consenting patients will be randomized 2:1 to receive either approximately 500 mL of CCP or standard of care. CCP will be collected from donors who have recovered from COVID-19 MESHD and who have detectable anti-SARS-CoV-2 antibodies quantified serologically. The primary outcome is intubation or death MESHD at Day 30. Secondary outcomes include ventilator free days, length of stay in intensive care or hospital, transfusion reactions, serious adverse events, and reduction in SARS-CoV-2 viral load.  Exploratory analyses include patients who received CCP containing high titre antibodies. A sample size of 1200 patients gives 80% power to detect a 25% relative risk reduction assuming a 30% baseline risk of intubation or death MESHD at 30 days (two-sided test; α =0.05). An interim analysis and sample size re-estimation will be done by an unblinded independent biostatistician after primary outcome data are available for 50% of the target recruitment (n= 600). Discussion: This trial will determine whether CCP will reduce intubation or death MESHD non-intubated adults with COVID-19 MESHD. The trial will also provide information on the role of and thresholds for SARS-CoV-2 antibody titers and neutralization assays for donor qualification.Trial registration: Clinicaltrials. gov HGNC NCT04348656; registered 16 April 2020; https://clinicaltrials. gov HGNC/ct2/show/NCT04348656?term=NCT04348656&draw=2&rank=1

    Increased RV:LV Ratio on Chest CT-Angiogram in COVID-19 MESHD is a Marker of Adverse Outcomes

    Authors: Ran Tao; Zuzana Burivalova; Sofia Carolina Masri; Naga Dharmavaram; Aurangzeb Baber; Roderick Deano; Timothy Hess; Ravi Dhingra; James Runo; Nizar Jarjour; Rebecca R Vanderpool; Naomi Chesler; Joanna E Kusmirek; Marlowe Eldridge; Christopher Francois; Farhan Raza

    doi:10.21203/rs.3.rs-267902/v1 Date: 2021-02-22 Source: ResearchSquare

    PurposeOur study aimed to use chest CT-angiogram (CTA) to assess if right ventricular (RV) dilation, quantified as an increased RV:LV (left ventricle) ratio, is associated with adverse outcomes in the novel coronavirus ( COVID-19 MESHD) infection.MethodsWe reviewed clinical, laboratory, and chest CTA findings in COVID-19 MESHD patients (n=100), and two control groups: normal subjects (n=10) and subjects with organizing pneumonia MESHD (n=10). On a chest CTA, we measured basal dimensions of the RV and LV in a focused 4-chamber view; and dimensions of pulmonary artery MESHD ( PA MESHD) and aorta (AO) at the PA MESHD bifurcation level. ResultsAmong the COVID-19 MESHD cohort, the mean age (±SD) was 55.1±14.9 years and 55% were female. A higher RV:LV ratio was correlated with adverse outcomes, defined as ICU admission, intubation, or death MESHD. In patients with adverse outcomes, the RV:LV ratio was 1.06±0.10, vs 0.95±0.15 in patients without adverse outcomes. Among the adverse outcomes group, compared to the control subjects with organizing pneumonia MESHD, the lung parenchymal damage MESHD was lower (22.6±9.0 vs 32.7±6.6), yet the RV:LV ratio was higher (1.06±0.14 vs 0.89±0.07). In ROC analysis, RV:LV ratio had an AUC= 0.707 with an optimal cut-off of RV:LV 1.1 as a predictor of adverse outcomes. In a validation cohort (n=25), an RV:LV ≥1.1 as a cut-off predicted adverse outcomes with an odds ratio of 76:1.ConclusionIn COVID-19 MESHD patients, RV:LV ratio ≥1.1 on CTA-chest is correlated with adverse outcomes. RV dilation in COVID-19 MESHD is out of proportion to parenchymal lung damage MESHD, pointing towards a vascular and/or thrombotic injury MESHD in the lungs.

    CLINICAL PERFORMANCE OF THE CALL SCORE FOR THE PREDICTION OF ADMISSION TO ICU AND DEATH IN HOSPITALIZED MESHD PATIENTS WITH COVID-19 MESHD PNEUMONIA IN A REFERENCE HOSPITAL IN PERU

    Authors: Rafael Pichardo-Rodriguez; Marcos Saavedra-Velasco; Willy Pena-Oscuvilca; Jhonnathan Ascarza-Saldana; Cesar Enrique Sanchez Alvarez; Gino Patron; Oscar Ruiz-Franco; Jhony A. De La Cruz-Vargas; Herney Andres Garcia Perdomo

    doi:10.1101/2021.02.09.21250884 Date: 2021-02-15 Source: medRxiv

    ObjectiveDetermine the CALL SCOREs diagnostic accuracy for the prediction of ICU admission and death MESHD in patients hospitalized for COVID-19 MESHD pneumonia MESHD in a reference hospital in Peru. MethodsWe performed an analytical cross-sectional observational study. We included patients with COVID-19 MESHD pneumonia MESHD treated at the "Dos de Mayo" National Hospital. Patients over 18 years old with a diagnosis confirmed by rapid or molecular testing were included. Those with an incomplete, illegible, or missing medical history and/or bacterial or fungal pneumonia MESHD were excluded. Data were extracted from medical records. The primary outcomes were mortality and admission to the ICU. The Call Score was calculated for each patient (4 to 13 points) and classified into three risk groups. Summary measures were presented for qualitative and quantitative variables. The area under the model curve and the operational characteristics (sensitivity, specificity) were calculated for the best cut-off point. ResultsThe Call Score reported an area under the curve of 0.59 (IC95%: 0.3 to 0.07), p = 0.43 for predicting death MESHD. However, for a cut-off point of 5.5, a sensitivity of 87%and a specificity of 65%were obtained. The area under the curve for ICU admission was 0.67 (95%CI: 0.3 to 0.07), p = 0.43; the 5.5 cut-off point showed a sensitivity of 82%and a specificity of 51%. ConclusionsThe Call Score shows a low performance for predicting mortality and admission to the ICU in Peruvian patients.

    Comparative Study of Hematological and Radiological Feature of Severe/ Critically MESHD Ill Patients with COVID-19 MESHD, Influenza A H7N9 and H1N1 Pneumonia

    Authors: Jindan Kong; Shan Wan; Sensen Shi; Songchao Cui; Xiangping Zong; Jun Wang; Jun Jin; Mo Zhu; Di Zou; Depei Wu; Jianhong Fu

    doi:10.21203/rs.3.rs-228013/v1 Date: 2021-02-09 Source: ResearchSquare

    Objectives This study aimed to explore useful clinical indexes for management of severe/ critically ill MESHD patients with COVID-19 MESHD, Influenza A H7N9 and H1N1 pneumonia MESHD by comparing hematological and radiological characteristics between them. Methods Severe/ critically ill MESHD patients with confirmed diagnosis of COVID-19 MESHD, Influenza A H7N9 and H1N1 pneumonia MESHD were retrospectively enrolled. The demographic data, clinical manifestations, hematological parameters, and radiological characteristics of three groups were compared. The influenza A was divided into two groups with/without patient death.Results In this study, 16 cases of COVID-19 MESHD, 10 cases of influenza A (H7N9), and 13 cases of influenza A (H1N1) who met severe/critically ill criteria were included. Compared with COVID-19 MESHD, the Influenza A (H7N9 and H1N1) groups had relatively more chronic diseases MESHD (80% and 92.3% vs 25%, P<0.05), higher APACHE Ⅱ scores (16.00 ± 8.63 and 15.08 ± 6.24, vs 5.50 ± 2.58, P<0.05) and higher mortality rates (40% and 46.2% vs 0%, P<0.05). The hematological finding indicated that Influenza A H7N9 and H1N1 patients had more significant lymphocytopenia MESHD (0.59 ± 0.31 × 109/L and 0.56 ± 0.35 × 109/L vs 0.97 ± 0.33 × 109/L, P < 0.05), elevated neutrophil to lymphocyte ratio (NLR; 14.67 ± 6.10 and 14.64 ± 10.36 vs 6.29 ± 3.72, P < 0.05) compared to COVID-19 MESHD. Especially in influenza A patients, NLR was significant different between the patients with or without death MESHD. Compared with the H7N9 group, ground glass opacity (GGO) on chest CT was more common in the COVID-19 MESHD group (P = 0.028), while pleural effusion MESHD was relatively rare (P = 0.001).ConclusionCompared to COVID-19 MESHD, patients with Influenza A (H7N9 and H1N1) had more underlying chronic diseases MESHD and higher mortality rates. The NLR can be used as a clinical parameter for the predication of risk stratification and outcome in COVID-19 MESHD and Influenza A pneumonia MESHD. Manifestations of pleural effusion MESHD or GGO in chest CT may be helpful for the identification of different viral pneumonia MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.